Journal of Antimicrobial Chemotherapy (2004) 53, ii11-ii21
© 2004 The British Society for Antimicrobial Chemotherapy
Supplement |
In vitro activity of ertapenem: review of recent studies
GLA VA Healthcare System and UCLA School of Medicine, Los Angeles, CA, USA
Abstract
Ertapenem is a long-acting, 1ß-methyl parenteral Group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-a-day dosing supported by clinical studies. Ertapenem is active against both Gram-positive and Gram-negative bacteria, including Enterobacteriaceae, Streptococcus pneumoniae and most species of anaerobic bacteria. Isolates from a variety of infections (intra-abdominal infections, skin/soft-tissue infections, community-acquired pneumonia, pelvic infections and urinary tract infections) are inhibited by ertapenem. It has restricted activity against nosocomial pathogens such as Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci. Ertapenem has potent activity against the majority of anaerobic isolates from intra-abdominal infections, and against most of the aerobes isolated from these infections, with the exceptions of the nosocomial pathogens mentioned above. MIC90s for most species of Enterobacteriaceae were <1 mg/L, significantly lower than those of imipenem. MIC90s for most Bacteroides fragilis group isolates ranged from 1 to 4 mg/L, and MIC90s were species specific for Clostridium, ranging from 0.06 mg/L for Clostridium perfringens to 4 mg/L for Clostridium clostridioforme. Ertapenem was equivalent to or better than piperacillin–tazobactam in activity against most anaerobic species isolated from these infections, and was more potent than piperacillin–tazobactam and ceftriaxone against the most common skin pathogens (e.g. methicillin-susceptible Staphylococcus aureus). Ertapenem was highly active against most of the pathogens isolated from patients with community-acquired pneumonia, except for isolates of methicillin-resistant S. aureus (which are infrequent causes of community-acquired infection); these isolates were also resistant to ceftriaxone. Resistance to ertapenem is most commonly attributable to a variety of mechanisms including alterations in penicillin-binding proteins in Gram-positive organisms, and combinations of potent metallo-ß-lactamase enzymes, porin protein defects and efflux pumps in Gram-negative organisms.
Keywords: susceptibility, resistance, carbapenems, antimicrobial agents
Footnotes
* Correspondence address. Wadsworth Anaerobe Laboratory, GLA VA Healthcare System, 11301 Wilshire Boulevard. 691/151J, USA. Tel: +1-310-268-3404; Fax: +1-310-268-4458; E-mail: hwexler{at}ucla.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Tanaka, H. Mikamo, K. Nakao, T. Ichiishi, T. Goto, Y. Yamagishi, and K. Watanabe In Vitro Activity of Tomopenem (CS-023/RO4908463) against Anaerobic Bacteria Antimicrob. Agents Chemother., January 1, 2009; 53(1): 319 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. d. Santos, J. R. Nicoli, W. A. Martins, S. C. Coutinho, A. C. M. Apolonio, C. G. Diniz, M. A. R. d. Carvalho, and L. d. M. Farias Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli J. Med. Microbiol., November 1, 2007; 56(11): 1576 - 1579. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Boselli, D. Breilh, S. Djabarouti, J. C. Bel, M. C. Saux, and B. Allaouchiche Diffusion of ertapenem into bone and synovial tissues J. Antimicrob. Chemother., October 1, 2007; 60(4): 893 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Valeria dos Santos, C. G. Diniz, S. C. Coutinho, A. C. M. Apolonio, L. Geralda de Sousa-Gaia, J. R. Nicoli, L. d. M. Farias, and M. A. Roque de Carvalho In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures J. Med. Microbiol., June 1, 2007; 56(6): 798 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. DeRyke, M. A. Banevicius, H. W. Fan, and D. P. Nicolau Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1481 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. A. Warren, K. L. Tyrrell, D. M. Citron, and E. J. C. Goldstein Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical Infections. J. Clin. Microbiol., July 1, 2006; 44(7): 2416 - 2422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1222 - 1227. [Abstract] [Full Text] [PDF]
|
|